Table 4.
Reported incidence, mortality and risk factors of gefitinib-induced interstitial lung disease (ILD) in Japanese [9,13-18] and Taiwanese [19] studies
| Year | Study group | No. of patients | No. cases of ILD (%) | No. ILD death (mortality, %) | Risk factor |
|---|---|---|---|---|---|
| 2004 | National Cancer Center, Japan [14] | 112 | 6 (5.4) | 4 (66.7) | Preexisting pulmonary fibrosis |
| 2005 | Okayama Lung Cancer Study Group [15] | 330 | 15 (4.5) | 8 (53.3) | Preexisting pulmonary fibrosis, poor PS, prior thoracic irradiation |
| 2006 | West Japan Thoracic Oncology Group [13] | 1,976 | 70 (3.5) | 31 (44.3) | Preexisting pulmonary fibrosis, male, smoking |
| 2008 | AstraZeneca [9] | 1,482 | 59 (4.0) | - (31.6) | Preexisting chronic ILD, poor PS, smoker, older age (> 55 years), recent NSCLC diagnosis, reduced normal lung on computed tomography scan, concurrent cardiac disease |
| 2009 | Japan-Multinational Trial Organization [16] | 526 | 17 (3.2) | 7 (41.2) | No risk factors found |
| 2010 | Okayama Lung Cancer Study Group [17] | 330 | 8 (2.4) | 5 (62.5) | Preexisting pulmonary fibrosis, poor PS |
| 2013 | NEJ 002 and WJTOG 3405 trials [18] | 201 (EGFR mutation positive) | 10 (5.0) | 2 (20.0) | Smoking |
| 2013 | Chang et al. [19] | 1,080 | 25 (2.3) | 10 (40.0) | Not evaluated |
| 2013 | This study | 1,114 | 15 (1.3) | 6 (40.0) | Lower albumin level |
PS, performance status; NSCLC, non-small cell lung cancer.